

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 1

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
= = = 2 BALANCE SHEET AFTER APPROPRIATION = = = < < < Amounts in thousands of EUR > > > >						
2.1.ASSETS						
2.1.1.FIXED ASSETS	20/28	20.971.536	75.052	21.046.587	54	81
A.Formation expenses	20	27.242	278	27.519	7	4
B.Intangible fixed assets	21	5.769.563	23.576	5.793.139	42	34
C.Tangible fixed assets	22/27	3.573.417	45.428	3.618.845	50	72
. Land and buildings	22	1.270.823	22.661	1.293.484	37	34
. Plant, machinery and equipment	23	881.769	12.690	894.458	48	53
. Furniture and vehicles	24	40.196	1.930	42.125	45	63
. Leasing and similar rights	25	42.247	6.048	48.295	17	10
. Other tangible fixed assets	26	20.944	772	21.717	18	19
. Assets under construction and advance payments	27	1.317.439	1.328	1.318.766	27	3
D.Financial fixed assets	28	11.601.314	5.770	11.607.083	46	46
. Affiliated enterprises	280/1	11.314.944	*	*	20	*
- Participating interests	280	10.494.539	*	*	19	*
- Amounts receivable	281	820.405	*	*	5	*
. Other enterprises linked by participating interests	282/3	269.606	*	*	4	*
- Participating interests	282	269.606	*	*	4	*
- Amounts receivable	283		*	*		*
. Other financial assets	284/8	16.763	*	*	42	*
- Shares	284	14.044	*	*	10	*
- Amounts receivable and cash guarantees	285/8	2.720	*	*	40	*
2.1.2.CURRENT ASSETS	29/58	18.198.749	88.568	18.287.317	55	93
A.Amounts receivable after more than one year	29	4.283.177	706	4.283.882	5	5
. Trade debtors	290	68	461	529	1	2
. Other amounts receivable	291	4.283.109	244	4.283.353	5	4
B.Stocks and contracts in progress	3	2.908.702	16.798	2.925.500	40	43
. Stocks	30/36	2.908.702	16.798	2.925.500	40	43
- Raw materials and consumables	30/31	808.024	*	*	35	*
- Work in progress	32	1.501.663	*	*	26	*
- Finished goods	33	523.969	*	*	30	*
- Goods purchased for resale	34	75.046	*	*	18	*
- Immovable property intended for sale	35		*	*		*
- Advance payments	36		*	*		*
. Contracts in progress	37					
C.Amounts receivable within one year	40/41	5.939.031	35.479	5.974.510	55	89
. Trade debtors	40	2.971.977	26.655	2.998.632	52	71
. Other amounts receivable	41	2.967.054	8.824	2.975.879	55	82
D.Current investments	50/53	4.711.179	6.383	4.717.562	12	16
. Own shares	50	8.842	*	*	2	*
. Other investments	51/53	4.702.337	*	*	12	*
E.Cash at bank and in hand	54/58	160.090	28.737	188.827	52	90
F.Deferred charges and accrued income	490/1	196.571	464	197.035	48	52
TOTAL ASSETS	20/58	39.170.285	163.619	39.333.905	55	93

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 2

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
2.2.EQUITY AND LIABILITIES						
2.2.1.EQUITY positive balance	10/15	29.473.975	71.113	29.545.088	52	74
EQUITY negative balance	10/15	-2.866	-2.622	-5.488	3	19
A.Capital	10	10.136.583	60.402	10.196.985	55	93
. Issued capital	100	10.143.668	62.633	10.206.301	55	93
. Uncalled capital	101	7.086	2.231	9.316	4	29
B.Share premium account	11	3.947.915	11.153	3.959.068	15	6
C.Revaluation surpluses	12	37.561	2.544	40.105	6	6
D.Reserves	13	10.399.543	23.459	10.423.002	46	66
. Legal reserve	130	503.193	820	504.014	46	65
. Reserves not available	131	97.272	332	97.603	14	3
- In respect of own shares held	1310	8.842		8.842	2	
- Other	1311	88.430	332	88.761	12	3
. Untaxed reserves	132	18.762	2.933	21.696	21	17
. Available reserves	133	9.780.315	19.374	9.799.689	21	44
E.Profit carried forward	(+) 14	5.229.875	10.673	5.240.548	36	28
Loss carried forward	(-) 14	-291.411	-43.166	-334.578	14	47
F.Investment grants	15	11.045	3.496	14.541	14	11
G.Advance to associates on the sharing out of the assets	19		71	71		1
2.2.2.PROVISIONS AND DEFERRED TAXES	16	747.124	1.827	748.952	37	16
A.Provisions for liabilities and charges	160/5	744.835	1.194	746.029	36	12
. Pensions and similar obligations	160	345.736	*	*	24	*
. Taxation	161	285	*	*	1	*
. Major repairs and maintenance	162	4.194	*	*	5	*
. Other liabilities and charges	163/5	394.620	*	*	26	*
B.Deferred taxes	168	2.289	633	2.922	11	6
2.2.3.AMOUNTS PAYABLE	17/49	8.952.051	93.301	9.045.353	54	92
A.Amounts payable after more than one year	17	2.611.208	27.232	2.638.441	29	45
. Financial debts	170/4	2.562.545	25.902	2.588.447	27	44
- Credit institutions, leasing and other similar obligations	172/3	58.693	19.022	77.715	20	33
* Leasing and similar obligations	172	39.532	*	*	14	*
* Credit institutions	173	19.161	*	*	12	*
- Other loans	174/0	2.503.852	6.880	2.510.732	15	22
* Subordinated loans	170	608.535	*	*	7	*
* Unsubordinated debentures	171	1.853.490	*	*	3	*
* Other loans	174	41.827	*	*	8	*
. Trade debts	175		80	80		1
- Suppliers	1750		*	*		*
- Bills of exchange payable	1751		*	*		*
. Advances received on contracts in progress	176					
. Other amounts payable	178/9	48.664	1.250	49.913	6	6
B.Amounts payable within one year	42/48	6.160.963	62.969	6.223.931	54	92
. Current portion of amounts payable after more than one year falling due within one year	42	592.808	4.819	597.627	23	41
. Financial debts	43	1.703.672	5.316	1.708.988	27	25
- Credit institutions	430/8	1.244.197	4.850	1.249.047	18	23
- Other loans	439	459.474	467	459.941	12	3
. Trade debts	44	2.579.001	28.062	2.607.063	54	87
- Suppliers	440/4	2.579.001	28.062	2.607.063	54	87
- Bills of exchange payable	441					
. Advances received on contracts in progress	46	2.710	15	2.725	6	1
. Taxes, remuneration and social security	45	539.937	5.770	545.706	51	70
- Taxes	450/3	72.128	2.445	74.573	43	65
- Remuneration and social security	454/9	467.809	3.325	471.133	49	41
. Other amounts payable	47/48	742.835	18.987	761.822	38	73
C.Deferred charges and accrued income	492/3	179.881	3.100	182.981	40	45
TOTAL LIABILITIES	10/49	39.170.285	163.619	39.333.905	55	93

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 3

				AMOUNTS			NUM. OF ENTERP.	
Codes				Complete	Abbreviated	Total	Comp.	Abbr.
= = = = 3 INCOME STATEMENT = = = =								
< < < Amounts in thousands of EUR > > >								
VALUE ADDED (EXCLUDING VAT) positive balance 9800				5.783.628	46.271	5.829.900	43	62
VALUE ADDED (EXCLUDING VAT) negative balance 9800				-11.140	-18.774	-29.915	12	31
A.OPERATING INCOME 70/74				13.648.160	*	*	52	*
. Turnover (optional entry for abridged layouts) 70				9.902.113	9.181	9.911.294	49	6
. Stocks and work and contracts in progress:								
increase (+) 71				200.393	*	*	16	*
decrease (-) 71				-10.556	*	*	14	*
. Own construction capitalised 72				1.881.027	*	*	16	*
. Other operating income 74				1.675.183	*	*	51	*
B.OPERATING CHARGES 60/64				12.663.194	*	*	55	*
. Goods for resale, raw and auxiliary materials services and miscellaneous (optional for abridged layouts) 60/61				7.875.672	7.718	7.883.390	55	9
. Raw materials, consumables 60				2.803.436	*	*	46	*
- Purchases 600/8				2.840.972	*	*	46	*
- Stocks:								
decrease (+) 609				68.773	*	*	16	*
increase (-) 609				-106.309	*	*	25	*
. Services and other goods 61				5.072.236	*	*	55	*
. Remuneration, social security and pensions 62				2.089.008	24.234	2.113.242	50	41
(+)/(-)								
. Depreciation of and other amounts written down formation expenses, intangible and tangible fixed assets 630				2.484.564	8.464	2.493.028	50	75
. Amounts written down stocks, contracts in progress and trade debtors :								
appropriations (+) 631/4				73.322	88	73.410	19	6
write-backs (-) 631/4				-4.467	-84	-4.551	11	2
. Provisions for risks and charges :								
appropriations (+) 635/7				104.310	226	104.536	16	7
uses and write-backs (-) 635/7				-23.423		-23.423	14	
. Other operating charges 640/8				64.208	704	64.912	54	91
. Operating charges carried to assets as restructuring costs (-) 649								
C.OPERATING PROFIT (+) 9901				1.068.981	17.216	1.086.196	37	50
OPERATING LOSS (-) 9901				-84.015	-23.349	-107.365	18	43
D.FINANCIAL INCOME 75				620.033	2.685	622.718	54	81
. Income from financial fixed assets 750				279.438	*	*	12	*
. Income from current assets 751				268.892	*	*	44	*
. Other financial income 752/9				71.703	*	*	51	*
E.FINANCIAL CHARGES 65				324.518	3.433	327.952	55	91
. Debt charges 650				212.930	*	*	50	*
. Amounts written down on current assets except stocks, contracts in progress and trade debtors: 651				-4.831	*	*	1	*
appropriations (write-backs) (+)/(-)								
. Other financial charges 652/9				116.419	*	*	55	*
F.PROFIT ON ORDINARY ACTIVITIES 9902				1.338.937	17.215	1.356.152	40	47
BEFORE TAXES (+)								
LOSS ON ORDINARY ACTIVITIES 9902				-58.456	-24.098	-82.554	15	46
BEFORE TAXES (-)								
G.EXTRAORDINARY INCOME 76				211.229	293	211.522	28	16
. Write-back of depreciation and of amounts written down intangible and tangible fixed assets 760				183	*	*	5	*
. Write-back of amounts written down financial fixed assets 761				12	*	*	1	*
. Write-back of provisions for extraordinary liabilities and charges 762				3.567	*	*	5	*
. Gains on disposal of fixed assets 763				1.860	*	*	14	*
. Other extraordinary income 764/9				205.608	*	*	15	*
H.EXTRAORDINARY CHARGES 66				88.106	337	88.444	32	17
. Extraordinary depreciation of and extraordinary amounts written down formation expenses intangible and tangible fixed assets 660				6.758	*	*	6	*
. Amounts written down financial fixed assets 661				12.391	*	*	4	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 4

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
financial fixed assets						
. Provisions for extraordinary liabilities and charges						
appropriations	(+) 662	20.009	*	*	3	*
uses	(-) 662	-638	*	*	2	*
. Losses on disposal of fixed assets	663	14.701	*	*	16	*
. Other extraordinary charges	664/8	34.885	*	*	16	*
. Extraordinary charges carried to assets as restructuring costs	(-) 669		*	*		*
I.PROFIT FOR THE PERIOD BEFORE TAXES	(+) 9903	1.483.340	17.292	1.500.632	39	51
LOSS FOR THE PERIOD BEFORE TAXES	(-) 9903	-79.737	-24.219	-103.956	16	42
J.TRANSFER FROM DEFERRED TAXES	780	2.698	49	2.747	9	6
K.TRANSFER TO DEFERRED TAXES	680					
L.INCOME TAXES	(-) 67/77	-1.063	-118	-1.180	5	3
INCOME TAXES	(+) 67/77	54.466	3.803	58.269	43	61
. Income taxes	670/3	55.534	*	*	47	*
. Adjustment of income taxes and write-back of tax provisions	77	2.131	*	*	16	*
M.PROFIT FOR THE PERIOD	(+) 9904	1.431.998	13.686	1.445.684	39	50
LOSS FOR THE PERIOD	(-) 9904	-79.100	-24.249	-103.350	16	43
N.TRANSFER FROM UNTAXED RESERVES	789	4.572	698	5.271	4	5
O.TRANSFER TO UNTAXED RESERVES	689	1.050	457	1.507	2	5
P.PROFIT FOR THE PERIOD TO BE APPROPRIATED	(+) 9905	1.435.497	13.911	1.449.408	39	51
LOSS FOR THE PERIOD TO BE APPROPRIATED	(-) 9905	-79.077	-24.233	-103.310	16	42
= = = = 4 APPROPRIATION ACCOUNT = = = = =						
< < < Amounts in thousands of EUR > > >						
A.Profit to be appropriated	(+) 9906	5.730.703	30.693	5.761.396	41	46
Loss to be appropriated	(-) 9906	-300.784	-43.123	-343.907	14	47
. Profit for the period avail. For appropri.	(+) 9905	1.435.497	13.911	1.449.408	39	51
Loss for the period avail. For appropri.	(-) 9905	-79.077	-24.233	-103.310	16	42
. Profit brought forward	(+) 14P	4.307.094	18.242	4.325.336	37	28
Loss brought forward	(-) 14P	-233.595	-20.350	-253.945	12	39
B.Transfers from capital and reserves	791/2	27.787	541	28.328	4	2
. from capital and share premium account	791	10.640	*	*	1	*
. from reserves	792	17.147	*	*	3	*
C.Transfers to capital and reserves	691/2	219.737	5.849	225.586	19	32
. to capital and share premium account	691		4	4		1
. to legal reserve	6920	15.380	152	15.532	15	14
. to other reserves	6921	204.357	5.694	210.051	7	27
D.Profit to be carried forward	(+) 14	5.229.875	10.673	5.240.548	36	28
Loss to be carried forward	(-) 14	-291.411	-43.166	-334.578	14	47
E.Partners' contribution in respect of losses	794	2.947		2.947	1	
F.Profit to be distributed	694/6	302.454	14.755	317.208	14	13
. Dividends	694	302.454	14.728	317.182	14	11
. Directors' or managers' entitlements	695		27	27		2
. Other beneficiaries	696					

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 5

		Codes	AMOUNTS			NUM. OF ENTERP.	
			Complete	Abbreviated	Total	Comp.	Abbr.
= = = = 5 EXPLANATORY DISCLOSURES = = = = =							
< < < Amounts in thousands of EUR > > >							
5.1.STATEMENT OF FORMATION EXPENSES							
Net book value at the end of the preceding period	20P		26.370	*	*	7	*
Movements during the period							
. New expenses incurred	8002		1.213	*	*	2	*
. Depreciation	8003		602	*	*	6	*
. Other (+)/(-)	8004			*	*		*
Net book value at the end of the period	20		27.242	*	*	7	*
Of which							
. Formation or capital increase expenses, loan issue expenses and other formation expenses	200/2		2	*	*	1	*
. Restructuring costs	204			*	*		*
5.2.STATEMENT OF INTANGIBLE FIXED ASSETS							
A.TOTAL OF INTANGIBLE ASSETS							
a)ACQUISITION VALUE							
At the end of the preceding period	8059P		22.406.332	17.175	22.423.507	45	41
Movements during the period							
. Acquisitions, including produced fixed assets	8029		2.321.024	17.848	2.338.872	34	20
. Sales and disposals	8039		22.290		22.290	8	
. Transfers from one heading to another (+)/(-)	8049		-3.067		-3.067	6	
At the end of the period	8059		24.701.999	35.023	24.737.022	46	47
b)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN							
At the end of the preceding period	8129P		16.890.340	9.234	16.899.574	45	40
Movements during the period							
. Recorded	8079		2.053.965	2.213	2.056.177	42	32
. Written back	8089						
. Acquisitions from third parties	8099		4.019		4.019	1	
. Cancelled owing to sales and disposals	8109		14.344		14.344	8	
. Transferred from one heading to another(+)/(-)	8119		-1.543		-1.543	3	
At the end of the period	8129		18.932.436	11.447	18.943.883	45	44
c)NET BOOK VALUE AT THE END OF THE PERIOD	21		5.769.563	23.576	5.793.139	42	34
B.BREAKDOWN OF INTANGIBLE FIXED ASSETS FOR COMPLETE FORMS							
5.2.1.RESEARCH AND DEVELOPMENT COSTS							
a)ACQUISITION VALUE							
At the end of the preceding period	8051P		20.245.834	*	*	18	*
Movements during the period							
. Acquisitions, including produced fixed assets	8021		1.814.549	*	*	12	*
. Sales and disposals	8031		1.643	*	*	1	*
. Transfers from one heading to another (+)/(-)	8041			*	*		*
At the end of the period	8051		22.058.740	*	*	19	*
b)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN							
At the end of the preceding period	8121P		15.833.476	*	*	18	*
Movements during the period							
. Recorded	8071		1.741.608	*	*	16	*
. Written back	8081			*	*		*
. Acquisitions from third parties	8091			*	*		*
. Cancelled owing to sales and disposals	8101		1.587	*	*	1	*
. Transferred from one heading to another(+)/(-)	8111			*	*		*
At the end of the period	8121		17.573.497	*	*	19	*
c)NET BOOK VALUE AT THE END OF THE PERIOD	210		4.485.242	*	*	16	*
5.2.2.CONCESSIONS, PATENTS, LICENCES AND SIMILAR RIGHTS							
a)ACQUISITION VALUE							
At the end of the preceding period	8052P		2.035.676	*	*	38	*
Movements during the period							
. Acquisitions, including produced fixed assets	8022		462.528	*	*	25	*
. Sales and disposals	8032		20.038	*	*	7	*
. Transfers from one heading to another (+)/(-)	8042		-3.067	*	*	6	*
At the end of the period	8052		2.475.098	*	*	39	*
b)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN							
At the end of the preceding period	8122P		945.938	*	*	38	*
Movements during the period							
. Recorded	8072		307.762	*	*	33	*
. Written back	8082			*	*		*
. Acquisitions from third parties	8092		4.019	*	*	1	*
. Cancelled owing to sales and disposals	8102		12.149	*	*	7	*
. Transferred from one heading to another(+)/(-)	8112		-1.543	*	*	3	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 6

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
At the end of the period	8122	1.244.026	*	*	38	*
c)NET BOOK VALUE AT THE END OF THE PERIOD	211	1.231.072	*	*	33	*
5.2.3.GOODWILL						
a)ACQUISITION VALUE						
At the end of the preceding period	8053P	124.823	*	*	11	*
Movements during the period						
. Acquisitions,	8023	43.947	*	*	3	*
including produced fixed assets						
. Sales and disposals	8033	608	*	*	1	*
. Transfers from one heading to another (+)/(-)	8043		*	*		*
At the end of the period	8053	168.161	*	*	12	*
b)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8123P	110.926	*	*	11	*
Movements during the period						
. Recorded	8073	4.595	*	*	7	*
. Written back	8083		*	*		*
. Acquisitions from third parties	8093		*	*		*
. Cancelled owing to sales and disposals	8103	608	*	*	1	*
. Transferred from one heading to another(+)/(-)	8113		*	*		*
At the end of the period	8123	114.913	*	*	12	*
c)NET BOOK VALUE AT THE END OF THE PERIOD	212	53.249	*	*	6	*
5.2.4.ADVANCE PAYMENTS						
a)ACQUISITION VALUE						
At the end of the preceding period	8054P		*	*		*
Movements during the period						
. Acquisitions,	8024		*	*		*
including produced fixed assets						
. Sales and disposals	8034		*	*		*
. Transfers from one heading to another (+)/(-)	8044		*	*		*
At the end of the period	8054		*	*		*
b)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8124P		*	*		*
Movements during the period						
. Recorded	8074		*	*		*
. Written back	8084		*	*		*
. Acquisitions from third parties	8094		*	*		*
. Cancelled owing to sales and disposals	8104		*	*		*
. Transferred from one heading to another(+)/(-)	8114		*	*		*
At the end of the period	8124		*	*		*
c)NET BOOK VALUE AT THE END OF THE PERIOD	213		*	*		*
5.3.STATEMENT OF TANGIBLE FIXED ASSETS						
A.TOTAL OF TANGIBLE FIXED ASSETS						
a)ACQUISITION VALUE						
At the end of the preceding period	8199P	8.463.379	86.070	8.549.449	50	67
Movements during the period						
. Acquisitions,	8169	749.196	14.059	763.255	46	59
including produced fixed assets						
. Sales and disposals	8179	131.539	1.074	132.613	33	26
. Transfers from one heading to another (+)/(-)	8189	2.570		2.570	11	
At the end of the period	8199	9.083.605	99.056	9.182.661	50	75
b)REVALUATION GAINS						
At the end of the preceding period	8259P	44.472	2.788	47.260	6	5
Movements during the period						
. Recorded	8219		724	724		1
. Acquisitions from third parties	8229					
. Cancelled	8239	364		364	1	
. Transferred from one heading to another(+)/(-)	8249					
At the end of the period	8259	44.108	3.512	47.619	6	6
c)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8329P	5.231.435	51.697	5.283.132	49	65
Movements during the period						
. Recorded	8279	431.083	6.172	437.255	49	70
. Written back	8289	183	5	187	5	1
. Acquisitions from third parties	8299					
. Cancelled owing to sales and disposals	8309	109.565	726	110.291	30	24
. Transferred from one heading to another(+)/(-)	8319	1.526		1.526	5	
At the end of the period	8329	5.554.296	57.139	5.611.435	49	73
d)NET BOOK VALUE AT THE END OF THE PERIOD	22/27	3.573.417	45.428	3.618.845	50	72
B.BREAKDOWN OF TANGIBLE FIXED ASSETS FOR COMPLETE FORMS						
5.3.1.LAND AND BUILDINGS						
a)ACQUISITION VALUE						
At the end of the preceding period	8191P	3.057.368	*	*	37	*
Movements during the period						
. Acquisitions,	8161	41.788	*	*	21	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 7

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
including produced fixed assets						
. Sales and disposals	8171	6.243	*	*	12	*
. Transfers from one heading to another (+)/(-)	8181	103.950	*	*	14	*
At the end of the period	8191	3.196.864	*	*	38	*
b) REVALUATION GAINS						
At the end of the preceding period	8251P	29.399	*	*	5	*
Movements during the period						
. Recorded	8211		*	*		*
. Acquisitions from third parties	8221		*	*		*
. Cancelled	8231	3	*	*	1	*
. Transferred from one heading to another (+)/(-)	8241		*	*		*
At the end of the period	8251	29.396	*	*	5	*
c) DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8321P	1.755.100	*	*	37	*
Movements during the period						
. Recorded	8271	157.404	*	*	37	*
. Written back	8281		*	*		*
. Acquisitions from third parties	8291		*	*		*
. Cancelled owing to sales and disposals	8301	5.814	*	*	10	*
. Transferred from one heading to another (+)/(-)	8311	48.748	*	*	4	*
At the end of the period	8321	1.955.437	*	*	38	*
d) NET BOOK VALUE AT THE END OF THE PERIOD	22	1.270.823	*	*	37	*
5.3.2. PLANT, MACHINERY AND EQUIPMENT						
a) ACQUISITION VALUE						
At the end of the preceding period	8192P	3.951.632	*	*	46	*
Movements during the period						
. Acquisitions, including produced fixed assets	8162	105.029	*	*	39	*
. Sales and disposals	8172	103.473	*	*	22	*
. Transfers from one heading to another (+)/(-)	8182	175.386	*	*	24	*
At the end of the period	8192	4.128.573	*	*	48	*
b) REVALUATION GAINS						
At the end of the preceding period	8252P	14.668	*	*	1	*
Movements during the period						
. Recorded	8212		*	*		*
. Acquisitions from third parties	8222		*	*		*
. Cancelled	8232	361	*	*	1	*
. Transferred from one heading to another (+)/(-)	8242		*	*		*
At the end of the period	8252	14.308	*	*	1	*
c) DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8322P	3.103.471	*	*	46	*
Movements during the period						
. Recorded	8272	226.969	*	*	47	*
. Written back	8282	165	*	*	3	*
. Acquisitions from third parties	8292		*	*		*
. Cancelled owing to sales and disposals	8302	96.062	*	*	21	*
. Transferred from one heading to another (+)/(-)	8312	26.899	*	*	9	*
At the end of the period	8322	3.261.113	*	*	48	*
d) NET BOOK VALUE AT THE END OF THE PERIOD	23	881.769	*	*	48	*
5.3.3. FURNITURE AND VEHICLES						
a) ACQUISITION VALUE						
At the end of the preceding period	8193P	222.029	*	*	45	*
Movements during the period						
. Acquisitions, including produced fixed assets	8163	11.033	*	*	33	*
. Sales and disposals	8173	6.462	*	*	23	*
. Transfers from one heading to another (+)/(-)	8183	14.560	*	*	16	*
At the end of the period	8193	241.160	*	*	45	*
b) REVALUATION GAINS						
At the end of the preceding period	8253P		*	*		*
Movements during the period						
. Recorded	8213		*	*		*
. Acquisitions from third parties	8223		*	*		*
. Cancelled	8233		*	*		*
. Transferred from one heading to another (+)/(-)	8243		*	*		*
At the end of the period	8253		*	*		*
c) DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8323P	182.225	*	*	45	*
Movements during the period						
. Recorded	8273	19.338	*	*	45	*
. Written back	8283	8	*	*	2	*
. Acquisitions from third parties	8293		*	*		*
. Cancelled owing to sales and disposals	8303	5.807	*	*	22	*
. Transferred from one heading to another (+)/(-)	8313	5.217	*	*	4	*
At the end of the period	8323	200.964	*	*	45	*
d) NET BOOK VALUE AT THE END OF THE PERIOD	24	40.196	*	*	45	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 8

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
5.3.4.LEASING AND SIMILAR RIGHTS						
a)ACQUISITION VALUE						
At the end of the preceding period	8194P	198.991	*	*	20	*
Movements during the period						
. Acquisitions,	8164	1.844	*	*	6	*
including produced fixed assets						
. Sales and disposals	8174	1.713	*	*	4	*
. Transfers from one heading to another (+)/(-)	8184	-75.269	*	*	7	*
At the end of the period	8194	123.852	*	*	18	*
b)REVALUATION GAINS						
At the end of the preceding period	8254P		*	*		*
Movements during the period						
. Recorded	8214		*	*		*
. Acquisitions from third parties	8224		*	*		*
. Cancelled	8234		*	*		*
. Transferred from one heading to another(+)/(-)	8244		*	*		*
At the end of the period	8254		*	*		*
c)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8324P	150.183	*	*	20	*
Movements during the period						
. Recorded	8274	8.878	*	*	18	*
. Written back	8284		*	*		*
. Acquisitions from third parties	8294		*	*		*
. Cancelled owing to sales and	8304	319	*	*	4	*
disposals						
. Transferred from one heading to another(+)/(-)	8314	-77.138	*	*	6	*
At the end of the period	8324	81.605	*	*	18	*
d)NET BOOK VALUE AT THE END OF THE PERIOD	25	42.247	*	*	17	*
OF WHICH						
Land and buildings	250	29.520	*	*	7	*
Plant, machinery and equipment	251	12.143	*	*	11	*
Furniture and vehicles	252	584	*	*	7	*
5.3.5.OTHER TANGIBLE FIXED ASSETS						
a)ACQUISITION VALUE						
At the end of the preceding period	8195P	52.672	*	*	22	*
Movements during the period						
. Acquisitions,	8165	1.886	*	*	9	*
including produced fixed assets						
. Sales and disposals	8175	2.217	*	*	8	*
. Transfers from one heading to another (+)/(-)	8185	911	*	*	6	*
At the end of the period	8195	53.251	*	*	21	*
b)REVALUATION GAINS						
At the end of the preceding period	8255P	404	*	*	1	*
Movements during the period						
. Recorded	8215		*	*		*
. Acquisitions from third parties	8225		*	*		*
. Cancelled	8235		*	*		*
. Transferred from one heading to another(+)/(-)	8245		*	*		*
At the end of the period	8255	404	*	*	1	*
c)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8325P	29.166	*	*	20	*
Movements during the period						
. Recorded	8275	4.346	*	*	15	*
. Written back	8285	9	*	*	1	*
. Acquisitions from third parties	8295		*	*		*
. Cancelled owing to sales and	8305	1.479	*	*	8	*
disposals						
. Transferred from one heading to another(+)/(-)	8315	688	*	*	2	*
At the end of the period	8325	32.711	*	*	18	*
d)NET BOOK VALUE AT THE END OF THE PERIOD	26	20.944	*	*	18	*
5.3.6.ASSETS UNDER CONSTRUCTION AND ADVANCE PAYMENTS						
a)ACQUISITION VALUE						
At the end of the preceding period	8196P	980.686	*	*	24	*
Movements during the period						
. Acquisitions,	8166	587.616	*	*	25	*
including produced fixed assets						
. Sales and disposals	8176	11.430	*	*	6	*
. Transfers from one heading to another (+)/(-)	8186	-216.968	*	*	22	*
At the end of the period	8196	1.339.904	*	*	27	*
b)REVALUATION GAINS						
At the end of the preceding period	8256P		*	*		*
Movements during the period						
. Recorded	8216		*	*		*
. Acquisitions from third parties	8226		*	*		*
. Cancelled	8236		*	*		*
. Transferred from one heading to another(+)/(-)	8246		*	*		*
At the end of the period	8256		*	*		*
c)DEPRECIATIONS AND AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8326P	11.290	*	*	5	*



Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 9

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
Movements during the period						
. Recorded	8276	14.147	*	*	2	*
. Written back	8286		*	*		*
. Acquisitions from third parties	8296		*	*		*
. Cancelled owing to sales and disposals	8306	84	*	*	1	*
. Transferred from one heading to another(+)/(-)	8316	-2.888	*	*	2	*
At the end of the period	8326	22.466	*	*	5	*
d)NET BOOK VALUE AT THE END OF THE PERIOD	27	1.317.439	*	*	27	*
5.4.STATEMENT OF FINANCIAL FIXED ASSETS						
SPECIFICALLY FOR ABRIDGED FORMS :						
a)ACQUISITION VALUE						
At the end of the preceding period	8395P	*	4.280	*	*	41
Movements during the period						
. Acquisitions	8365	*	1.862	*	*	18
. Sales and disposals	8375	*	154	*	*	9
. Transfers from one heading to another (+)/(-)	8385	*		*	*	
. Other movements	8386	*	-99	*	*	2
At the end of the period	8395	*	5.889	*	*	46
b)REVALUATION GAINS						
At the end of the preceding period	8455P	*		*	*	
Movements during the period						
. Recorded	8415	*		*	*	
. Acquisitions from third parties	8425	*		*	*	
. Cancelled	8435	*		*	*	
. Transferred from one heading to another(+)/(-)	8445	*		*	*	
At the end of the period	8455	*		*	*	
c)AMOUNTS WRITTEN DOWN STOCKS						
At the end of the preceding period	8525P	*	120	*	*	2
Movements during the period						
. Recorded	8475	*		*	*	
. Written back	8485	*		*	*	
. Acquisitions from third parties	8495	*		*	*	
. Cancelled owing to sales and disposals	8505	*		*	*	
. Transferred from one heading to another(+)/(-)	8515	*		*	*	
At the end of the period	8525	*	120	*	*	2
d)UNCALLED AMOUNTS						
At the end of the preceding period	8555P	*		*	*	
Movements during the period (+)/(-)	8545	*		*	*	
At the end of the period	8555	*		*	*	
e)NET BOOK VALUE AT THE END OF THE PERIOD	28	*	5.770	*	*	46
SPECIFICALLY FOR COMPLETE FORMS :						
A.TOTAL OF FINANCIAL FIXED ASSETS						
A.1.PARTICIPATING INTERESTS AND SHARES : TOTAL						
a)ACQUISITION VALUE						
At the end of the preceding period	8394P	10.661.348	*	*	24	*
Movements during the period						
. Acquisitions	8364	281.979	*	*	8	*
. Sales and disposals	8374	25.551	*	*	6	*
. Transfers from one heading to another (+)/(-)	8384		*	*		*
At the end of the period	8394	10.917.775	*	*	23	*
b)REVALUATION GAINS						
At the end of the preceding period	8454P	469	*	*	2	*
Movements during the period						
. Recorded	8414		*	*		*
. Acquisitions from third parties	8424		*	*		*
. Cancelled	8434		*	*		*
. Transferred from one heading to another(+)/(-)	8444		*	*		*
At the end of the period	8454	469	*	*	2	*
c)AMOUNTS WRITTEN DOWNS						
At the end of the preceding period	8524P	130.293	*	*	9	*
Movements during the period						
. Recorded	8474	9.700	*	*	4	*
. Written back	8484	12	*	*	1	*
. Acquisitions from third parties	8494		*	*		*
. Cancelled owing to sales and disposals	8504		*	*		*
. Transferred from one heading to another(+)/(-)	8514		*	*		*
At the end of the period	8524	139.981	*	*	8	*
d)UNCALLED AMOUNTS						
At the end of the preceding period	8554P	74	*	*	2	*
Movements during the period (+)/(-)	8544		*	*		*
At the end of the period	8554	74	*	*	2	*
e)NET BOOK VALUE AT THE END OF THE PERIOD	8564	10.778.189	*	*	22	*
A.2.TOTAL AMOUNTS RECEIVABLE						
a)NET BOOK VALUE AT THE END OF	8644P	859.918	*	*	44	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 10

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
THE PRECEDING PERIOD						
b)MOVEMENTS DURING THE PERIOD						
. Additions	8584	41.305	*	*	12	*
. Repayments	8594	71.347	*	*	21	*
. Amounts written down	8604	2.691	*	*	1	*
. Amounts written back	8614		*	*		*
. Exchange differences (+)/(-)	8624	-1.105	*	*	2	*
. Others (+)/(-)	8634	-2.956	*	*	2	*
c)NET BOOK VALUE AT THE END OF THE PERIOD	8644	823.125	*	*	42	*
d)ACCUMULATED AMOUNTS WRITTEN OFF ON AMOUNTS RECEIVABLE AT THE END OF THE PERIOD	8654	4.832	*	*	1	*
B.BREAKDOWN OF FINANCIAL FIXED ASSETS FOR COMPLETE FORMS						
5.4.1.AFFILIATED ENTERPRISES						
1.1.PARTICIPATING INTERESTS AND SHARES						
a)ACQUISITION VALUE						
At the end of the preceding period	8391P	10.328.987	*	*	20	*
Movements during the period						
. Acquisitions	8361	281.465	*	*	7	*
. Sales and disposals	8371	25.347	*	*	4	*
. Transfers from one heading to another (+)/(-)	8381		*	*		*
At the end of the period	8391	10.585.105	*	*	19	*
b)REVALUATION GAINS						
At the end of the preceding period	8451P	469	*	*	2	*
Movements during the period						
. Recorded	8411		*	*		*
. Acquisitions from third parties	8421		*	*		*
. Cancelled	8431		*	*		*
. Transferred from one heading to another(+)/(-)	8441		*	*		*
At the end of the period	8451	469	*	*	2	*
c)AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8521P	87.457	*	*	8	*
Movements during the period						
. Recorded	8471	3.518	*	*	2	*
. Written back	8481	12	*	*	1	*
. Acquisitions from third parties	8491		*	*		*
. Cancelled owing to sales and disposals	8501		*	*		*
. Transferred from one heading to another(+)/(-)	8511		*	*		*
At the end of the period	8521	90.963	*	*	7	*
d)UNCALLED AMOUNTS						
At the end of the preceding period	8551P	71	*	*	2	*
Movements during the period (+)/(-)	8541		*	*		*
At the end of the period	8551	71	*	*	2	*
e)NET BOOK VALUE AT THE END OF THE PERIOD	280	10.494.539	*	*	19	*
1.2.AMOUNTS RECEIVABLE						
a)NET BOOK VALUE	281P	850.172	*	*	5	*
AT THE END OF THE PRECEDING PERIOD						
b)MOVEMENTS DURING THE PERIOD						
. Additions	8581	41.156	*	*	3	*
. Repayments	8591	67.128	*	*	3	*
. Amounts written down	8601	2.691	*	*	1	*
. Amounts written back	8611		*	*		*
. Exchange differences (+)/(-)	8621	-1.105	*	*	1	*
. Other movements (+)/(-)	8631		*	*		*
c)NET BOOK VALUE AT THE END OF THE PERIOD	281	820.405	*	*	5	*
d)ACCUMULATED AMOUNTS WRITTEN OFF ON AMOUNTS RECEIVABLE AT THE END OF THE PERIOD	8651	4.832	*	*	1	*
5.4.2.ENTERPRISES LINKED BY A PARTICIPATING INTEREST -						
2.1.PARTICIPATING INTERESTS AND SHARES						
a)ACQUISITION VALUE						
At the end of the preceding period	8392P	293.362	*	*	6	*
Movements during the period						
. Acquisitions	8362		*	*		*
. Sales and disposals	8372		*	*		*
. Transfers from one heading to another (+)/(-)	8382	-278	*	*	1	*
At the end of the period	8392	293.084	*	*	5	*
b)REVALUATION GAINS						
At the end of the preceding period	8452P		*	*		*
Movements during the period						
. Recorded	8412		*	*		*
. Acquisitions from third parties	8422		*	*		*
. Cancelled	8432		*	*		*
. Transferred from one heading to another(+)/(-)	8442		*	*		*
At the end of the period	8452		*	*		*
c)AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8522P	18.074	*	*	3	*
Movements during the period						
. Recorded	8472	5.404	*	*	1	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 11

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Written back	8482		*	*		*
. Acquisitions from third parties	8492		*	*		*
. Cancelled owing to sales and disposals	8502		*	*		*
. Transferred from one heading to another(+)/(-)	8512		*	*		*
At the end of the period	8522	23.478	*	*	3	*
d)UNCALLED AMOUNTS						
At the end of the preceding period	8552P		*	*		*
Movements during the period (+)/(-)	8542		*	*		*
At the end of the period	8552		*	*		*
e)NET BOOK VALUE AT THE END OF THE PERIOD	282	269.606	*	*	4	*
2.2.AMOUNTS RECEIVABLE						
a)NET BOOK VALUE AT THE END OF THE PRECEDING PERIOD	283P		*	*		*
b)MOVEMENTS DURING THE PERIOD						
. Additions	8582		*	*		*
. Repayments	8592		*	*		*
. Amounts written down	8602		*	*		*
. Amounts written back	8612		*	*		*
. Exchange differences (+)/(-)	8622		*	*		*
. Other movements (+)/(-)	8632		*	*		*
c)NET BOOK VALUE AT THE END OF THE PERIOD	283		*	*		*
d)ACCUMULATED AMOUNTS WRITTEN OFF ON AMOUNTS RECEIVABLE AT THE END OF THE PERIOD	8652		*	*		*
5.4.3.OTHER ENTERPRISES						
3.1.PARTICIPATING INTERESTS AND SHARES						
a)ACQUISITION VALUE						
At the end of the preceding period	8393P	38.998	*	*	8	*
Movements during the period						
. Acquisitions	8363	514	*	*	3	*
. Sales and disposals	8373	204	*	*	2	*
. Transfers from one heading to another (+)/(-)	8383	278	*	*	1	*
At the end of the period	8393	39.586	*	*	10	*
b)REVALUATION GAINS						
At the end of the preceding period	8453P		*	*		*
Movements during the period						
. Recorded	8413		*	*		*
. Acquisitions from third parties	8423		*	*		*
. Cancelled	8433		*	*		*
. Transferred from one heading to another(+)/(-)	8443		*	*		*
At the end of the period	8453		*	*		*
c)AMOUNTS WRITTEN DOWN						
At the end of the preceding period	8523P	24.762	*	*	1	*
Movements during the period						
. Recorded	8473	778	*	*	2	*
. Written back	8483		*	*		*
. Acquisitions from third parties	8493		*	*		*
. Cancelled owing to sales and disposals	8503		*	*		*
. Transferred from one heading to another(+)/(-)	8513		*	*		*
At the end of the period	8523	25.540	*	*	2	*
d)UNCALLED AMOUNTS						
At the end of the preceding period	8553P	2	*	*	1	*
Movements during the period (+)/(-)	8543		*	*		*
Uncalled amounts	8553	2	*	*	1	*
At the end of the period						
e)NET BOOK VALUE AT THE END OF THE PERIOD	284	14.044	*	*	10	*
3.2.AMOUNTS RECEIVABLE						
a)NET BOOK VALUE AT THE END OF THE PRECEDING PERIOD	285/8P	9.745	*	*	42	*
b)MOVEMENTS DURING THE PERIOD						
. Additions	8583	149	*	*	11	*
. Repayments	8593	4.219	*	*	20	*
. Amounts written down	8603		*	*		*
. Amounts written back	8613		*	*		*
. Exchange differences (+)/(-)	8623	0	*	*	1	*
. Other movements (+)/(-)	8633	-2.956	*	*	2	*
c)NET BOOK VALUE AT THE END OF THE PERIOD	285/8	2.720	*	*	40	*
d)ACCUMULATED AMOUNTS WRITTEN OFF ON AMOUNTS RECEIVABLE AT THE END OF THE PERIOD	8653		*	*		*
5.6.OTHER INVESTMENTS AND DEPOSITS						
. Shares	51	7.286	*	*	4	*
- Book value increased with the uncalled amount	8681	7.286	*	*	4	*
- Uncalled amount	8682		*	*		*
. Fixed income securities	52		*	*		*
- Fixed income securities issued by credit institutions	8684		*	*		*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 12

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Term accounts with credit institutions	53	961.464	*	*	3	*
. With residual term or notice of withdrawal						
- up to one month	8686	955.452	*	*	1	*
- between one month and one year	8687	6.011	*	*	2	*
- over one year	8688		*	*		*
. Other investments not mentioned above	8689	3.733.587	*	*	6	*
5.7.STATEMENT OF CAPITAL						
A.Social capital						
. Issued capital	100P	9.782.259	35.749	9.818.008	54	81
At the end of the preceding period						
. Issued capital at the end of the period	100	10.143.668	62.633	10.206.301	55	93
B.Structure of the capital						
. Number of registered shares	8702	202.057.421	*	*	44	*
. Number of bearer shares	8703	292.709.588	*	*	5	*
C.Capital not paid						
. Uncalled capital	101	7.086	2.231	9.316	4	29
. Called up capital, unpaid	8712					
D.Own shares						
. Held by the company itself						
- Amount of capital held	8721	1.112		1.112	2	
- Corresponding number of shares	8722	378.507		378.507	2	
. Held by the subsidiaries						
- Amount of capital held	8731					
- Corresponding number of shares	8732					
E.Commitments to issue shares						
. Owing to the exercise of conversion rights						
- Amount of outstanding convertible loans	8740		300	300		1
- Amount of capital to be subscribed	8741		300	300		1
- Corresponding maximum number of shares to be issued	8742		19.824	19.824		1
. Owing to exercise of subscription rights						
- Number of outstanding subscription rights	8745	7.590.665	1.310.444	8.901.109	3	2
- Amount of capital to be subscribed	8746	2.153	1.009	3.162	3	2
- Corresponding maximum number of shares to be issued	8747	7.590.665	1.310.444	8.901.109	3	2
F.Authorized capital not issued	8751	12.557		12.557	3	
G.Shares issued, non representing capital						
. Distribution						
- Number of shares	8761	5.458.920		5.458.920	2	
- Number of voting rights attached	8762	5.458.920		5.458.920	2	
. Allocation shareholders						
- Number of shares held by the company itself	8771					
- Number of shares held by its subsidiaries	8781					
5.9.STATEMENT OF AMOUNTS PAYABLE						
A.BREAKDOWN OF AMOUNTS PAYABLE WITH AN ORIGINAL PERIOD TO MATURITY OF MORE THAN ONE YEAR, ACCORDING TO THEIR RESIDUAL TERM						
A.1.Current portion of amounts payable after more than one year falling due within one year						
. Financial debts	8801	591.158	*	*	23	*
- Subordinated loans	8811	260	*	*	2	*
- Unsubordinated debentures	8821	574.845	*	*	3	*
- Leasing and similar obligations	8831	10.268	*	*	14	*
- Credit institutions	8841	5.437	*	*	13	*
- Other loans	8851	349	*	*	2	*
. Trade debts	8861		*	*		*
- Suppliers	8871		*	*		*
- Bills of exchange payable	8881		*	*		*
. Advances received on contracts in progress	8891		*	*		*
. Other amounts payable	8901	1.650	*	*	2	*
Total current portion of amounts payable after more than one year falling due within one year	42	592.808	4.819	597.627	23	41
A.2.Amounts payable with a remaining term of more than one but not more than five years						
. Financial debts	8802	1.686.356	*	*	27	*

NACE-BEL2008: + 21\*

P. 13

		Codes	AMOUNTS			NUM. OF ENTERP.	
			Complete	Abbreviated	Total	Comp.	Abbr.
	- Subordinated loans	8812	607.761	*	*	7	*
	- Unsubordinated debentures	8822	1.000.898	*	*	3	*
	- Leasing and similar obligations	8832	28.427	*	*	13	*
	- Credit institutions	8842	12.014	*	*	11	*
	- Other loans	8852	37.256	*	*	7	*
	. Trade debts	8862		*	*		*
	- Suppliers	8872		*	*		*
	- Bills of exchange payable	8882		*	*		*
	. Advances received on contracts in progress	8892		*	*		*
	. Other amounts payable	8902	38.059	*	*	4	*
	Total amounts payable with a remaining term of more than one but not more than five years	8912	1.724.415	16.495	1.740.910	28	40
A.3.Amounts payable with a remaining term of more than five years							
	. Financial debts	8803	876.189	*	*	14	*
	- Subordinated loans	8813	775	*	*	1	*
	- Unsubordinated debentures	8823	852.592	*	*	2	*
	- Leasing and similar obligations	8833	11.104	*	*	4	*
	- Credit institutions	8843	7.147	*	*	5	*
	- Other loans	8853	4.571	*	*	3	*
	. Trade debts	8863		*	*		*
	- Suppliers	8873		*	*		*
	- Bills of exchange payable	8883		*	*		*
	. Advances received on contracts in progress	8893		*	*		*
	. Other amounts payable	8903	10.605	*	*	2	*
	Total amounts payable with a remaining term of more than five years	8913	886.794	10.737	897.531	15	27
B.GUARANTEED AMOUNTS PAYABLE							
B.1.Amounts payable guaranteed by Belgian public authorities							
	. Financial debts	8921					
	- Credit institutions, leasing and similar obligations	891					
	* Leasing and similar obligations	8951		*	*		*
	* Credit institutions	8961		*	*		*
	- Other loans	901					
	* Subordinated loans	8931		*	*		*
	* Unsubordinated debentures	8941		*	*		*
	- Other loans	8971		*	*		*
	. Trade debts	8981					
	- Suppliers	8991					
	- Bills of exchange payable	9001					
	. Advances received on contracts in progress	9011					
	. Taxes, remuneration and social security	9021					
	. Other amounts payable	9051					
	Total amounts payable guaranteed by Belgian public authorities	9061					
B.2.Amounts payable guaranteed by real securities or irrevocably promised by the enterprise on its own assets							
	. Financial debts	8922	34.393	8.769	43.162	9	14
	- Credit institutions, leasing and similar obligations	892	31.393	8.463	39.856	9	13
	* Leasing and similar obligations	8952	3.547	*	*	4	*
	* Credit institutions	8962	27.846	*	*	7	*
	- Other loans	902	3.000	306	3.306	1	2
	* Subordinated loans	8932	3.000	*	*	1	*
	* Unsubordinated debentures	8942		*	*		*
	- Other loans	8972		*	*		*
	. Trade debts	8982					
	- Suppliers	8992					
	- Bills of exchange payable	9002					
	. Advances received on contracts in progress	9012					
	. Taxes, remuneration and social security	9022					
	- Taxes	9032					
	- Remuneration and social security	9042					
	. Other amounts payable	9052					
	Total amounts payable guaranteed by real securities or irrevocably promised by the enterprise on its own assets	9062	34.393	8.769	43.162	9	14
C.AMOUNTS PAYABLE FOR TAXES, REMUNERATION AND SOCIAL SECURITY							

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 14

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
C.1.Taxes						
. Outstanding tax debts	9072	59		59	1	
. Accruing taxes payable	9073	30.269	*	*	40	*
. Estimated taxes payable	450	41.800	*	*	17	*
C.2.Remuneration and social security						
. Amounts due to the National Social Security Office	9076	142		142	2	
. Other amounts payable in respect of remuneration and social security	9077	467.666	*	*	49	*
5.10.OPERATING RESULTS						
A.OPERATING INCOME						
Other operating income						
Operating subsidies and compensatory amounts received from public authorities	740	20.016	*	*	12	*
B.OPERATING CHARGES						
a)Employees recorded in the personnel register						
. Total number at the closing date	9086	22.551	562	23.113	49	38
. Average number of employees calculated in full-time equivalents	9087	21.344	508	21.852	49	41
. Number of actual worked hours	9088	31.955.229	792.208	32.747.437	49	39
b)Personnel costs						
. Remuneration and direct social benefits	620	1.427.672	16.984	1.444.656	49	41
. Employer's contribution for social security	621	439.205	5.314	444.520	50	39
. Employers' premiums for extra statutory insurance	622	80.153	227	80.380	45	11
. Other personnel costs	623	82.658	1.705	84.363	50	37
. Pensions	624	59.319	4	59.323	14	1
c)Provisions for pensions						
. Appropriations (uses and write-backs) (+)/(-)	635	27.287	*	*	24	*
d)Amounts written down						
. On stocks and contracts in progress						
- Recorded	9110	73.579	*	*	21	*
- Written back	9111	9.191	*	*	12	*
. On trade debts						
- Recorded	9112	5.352	*	*	15	*
- Written back	9113	884	*	*	10	*
e)Provisions for liabilities and charges						
. Formed	9115	147.598	*	*	23	*
. Used and written back	9116	66.710	*	*	24	*
f)Other operating charges						
. Taxes related to operation	640	50.535	*	*	49	*
. Other costs	641/8	13.673	*	*	39	*
g)Hired temporary staff and personnel placed at the enterprise's disposal						
. Total number at the closing date	9096	716	*	*	16	*
. Average number calculated in full-time equivalents	9097	1.219	*	*	34	*
. Number of actual worked hours	9098	2.296.662	*	*	34	*
. Costs to the enterprise	617	72.834	*	*	34	*
5.11.FINANCIAL RESULTS						
a)Other financial income						
Subsidies granted by public authorities and recorded as income for the period						
- Capital subsidies	9125	1.970	427	2.397	12	6
- Interest subsidies	9126					
b)Depreciation of loan issue expenses and reimbursement premiums	6501	2.739	*	*	1	*
c)Interests recorded under assets	6503					
d)Amounts written down on current assets						
. Recorded	6510		*	*		*
. Written back	6511	4.831	*	*	1	*
e)Other financial charges						
. Charges for discounting amounts receivable	653	353	2	355	6	1
f)Provisions of a financial nature						
. Formed	656	-238	6	-232	1	2
. Used and written back	6560		*	*		*
	6561	238	*	*	1	*
5.12.INCOME TAXES AND OTHER TAXES						
A.INCOME TAXES						
Income taxes on the result of the current period	9134	54.693	*	*	43	*
- Income taxes paid and withholding taxes due or paid	9135	44.429	*	*	40	*
- Excess of income tax prepayments and	9136	5.270	*	*	5	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 15

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
withholding taxes paid included in assets						
- Estimated taxes payable	9137	15.534	*	*	18	*
. Income taxes on the result of prior periods	9138	841	*	*	15	*
- Additional income taxes due or paid	9139	824	*	*	14	*
- Additional income taxes estimated or provided for	9140	17	*	*	1	*
. Status of deferred taxes						
- Deferred taxes representing assets	9141	3.645.429	*	*	23	*
Accumulated tax losses deductible from future taxable profits	9142	2.553.951	*	*	19	*
- Deferred taxes representing liabilities	9144	108	*	*	1	*
B.VALUE ADDED TAXES AND OTHER TAXES BORNE BY THIRD PARTIES						
. Value added taxes charged						
- To the enterprise (deductible)	9145	1.879.447	*	*	53	*
- By the enterprise	9146	1.651.971	*	*	50	*
. Amounts withheld on behalf of third party						
- For payroll withholding taxes	9147	423.238	*	*	50	*
- For withholding taxes on investment income	9148	21.175	*	*	15	*
5.13.RIGHTS AND COMMITMENTS NOT REFLECTED IN THE BALANCE SHEET						
A.PERSONAL GUARANTEES PROVIDED OR IRREVOCABLY PROMISED BY THE ENTERPRISE AS SECURITY FOR DEBTS AND COMMITMENTS OF THIRD PARTIES	9149	264.378	214	264.592	3	1
Of which						
. Bills of exchange in circulation endorsed by the enterprise	9150					
. Bills of exchange in circulation drawn or guaranteed by the enterprise	9151		*	*		*
. Maximum amount up to which other debts or commitments of third parties are guaranteed by the enterprise	9153	264.378	*	*	3	*
B.REAL GUARANTEES						
a)Real guarantees provided or irrevocably promised by the enterprise on its own assets as security of debts and commitments of the enterprise						
. Mortgages						
- Book value of immovable properties mortgaged	9161	3.352	10.811	14.163	3	12
- Amount of registration	9171	14.151	16.785	30.936	3	12
. Pledging of goodwill - Amount of registration	9181	29.789	5.659	35.448	8	9
. Pledging of other assets - Book value of other assets pledged	9191	22.666	21	22.688	4	1
. Guarantees provided on future assets - Amount of assets involved	9201					
b)Real guarantees provided or irrevocably promised by the enterprise on its own assets as security of debts and commitments of third parties						
. Mortgages						
- Book value of immovable properties mortgaged	9162	464.600		464.600	1	
- Amount of registration	9172	10.500		10.500	1	
. Pledging of goodwill - Amount of registration	9182					
. Pledging of other assets - Book value of assets pledged	9192					
. Guarantees provided on future assets - Amounts of assets involved	9202					
C.FORWARD TRANSACTIONS						
. Goods purchased (to be received)	9213		*	*		*
. Goods sold (to be delivered)	9214		*	*		*
. Currencies purchased (to be received)	9215	1.229.595	*	*	4	*
. Currencies sold (to be delivered)	9216	2.789.697	*	*	5	*
D.PENSIONS FUNDED BY THE ENTERPRISE						
Estimated amount of the commitments resulting for the enterprise from past services	9220	6.570	*	*	1	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 16

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
5.14.RELATIONSHIPS WITH AFFILIATED ENTERPRISES AND ENTERPRISES LINKED BY PARTICIPATING INTERESTS						
A.AFFILIATED ENTERPRISES						
a)Financial fixed assets	280/1	11.314.944	*	*	20	*
. Participating interests	280	10.494.539	*	*	19	*
. Subordinated amounts receivable	9271		*	*		*
. Other amounts receivable	9281	820.405	*	*	5	*
b)Amounts receivable from affiliated enterprises	9291	7.289.816	4.332	7.294.149	39	8
. Over one year	9301	2.145.412	*	*	2	*
. Within one year	9311	5.144.404	*	*	39	*
c)Current investments in affiliated enterprises	9321	4.579.377	*	*	2	*
. Shares	9331		*	*		*
. Amounts receivable	9341	4.579.377	*	*	2	*
d)Amounts payable	9351	2.742.428	*	*	39	*
. Over one year	9361	366.858	*	*	10	*
. Within one year	9371	2.375.570	*	*	38	*
e)Personal and real guarantees						
. Provided or irrevocably promised by the enterprise as security for debts or commitments of affiliated enterprises (complete forms)	9381	870.577	*	*	5	*
. Guarantees provided in favour of affiliated enterprises (abbreviated forms)	9294	*		*	*	
. Provided or irrevocably promised by affiliated enterprises as security for debts or commitments of the enterprise	9391	249.849	*	*	4	*
f)Other significant financial commitments						
. Specifically for complete models	9401		*	*		*
. Specifically for abridged models	9295	*		*	*	
g)Financial results						
. Income from financial fixed assets	9421	279.192	*	*	5	*
. Income from current assets	9431	245.163	*	*	17	*
. Other financial income	9441	2.275	*	*	2	*
. Debt charges	9461	56.991	*	*	21	*
. Other financial charges	9471	1.905	*	*	3	*
h)Disposal of fixed assets						
. Capital gains obtained	9481		*	*		*
. Capital losses suffered	9491		*	*		*
B.ENTERPRISES LINKED BY PARTICIPATION						
a)Financial fixed assets	282/3	269.606	*	*	4	*
. Participating interests	282	269.606	*	*	4	*
. Subordinated amounts receivable	9272		*	*		*
. Other amounts receivable	9282		*	*		*
b)Amounts receivable	9292	2.021	*	*	2	*
. Over one year	9302	1.428	*	*	1	*
. Within one year	9312	593	*	*	2	*
c)Amounts payable	9352	6.681	*	*	2	*
. Over one year	9362	3.240	*	*	1	*
. Within one year	9372	3.441	*	*	1	*
5.15.FINANCIAL RELATIONSHIPS WITH THE						
A.DIRECTORS, MANAGERS, INDIVIDUALS OR BODIES CORPORATE WHO CONTROL THE ENTERPRISE WITHOUT BEING ASSOCIATED THEREWITH OR OTHER ENTERPRISES CONTROLLED BY THESE PERSONS						
. Amounts receivable from these persons	9500	130	76	206	3	1
. Guarantees provided in their favour	9501					
. Other significant commitments undertaken in their favour	9502					
. Amount of direct and indirect remunerations and pensions, included in the income statement, as long as this disclosure does not concern exclusively or mainly, the situation of a single identifiable person						
- To directors and managers	9503	9.071	*	*	11	*
- To former directors and former managers	9504	212	*	*	1	*
B.AUDITORS OR PEOPLE THEY ARE LINKED TO						



Year 2013                      Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 17

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Auditor's fees	9505	3.082	*	*	48	*
. Fees for exceptional services or special missions executed in the company by the auditor						
- Other attestation missions	95061	143	*	*	7	*
- Tax consultancy	95062	3	*	*	1	*
- Other missions external to the audit	95063	212	*	*	5	*
. Fees for exceptional services or special missions executed in the company by people they are linked to						
- Other attestation missions	95081		*	*		*
- Tax consultancy	95082	175	*	*	7	*
- Other missions external to the audit	95083	104	*	*	5	*
5.17.INFORMATION RELATING TO CONSOLIDATED ACCOUNTS						
FINANCIAL RELATIONSHIPS OF THE GROUP LED BY THE ENTERPRISE IN BELGIUM WITH AUDITORS OR WITH PEOPLE THEY ARE LINKED TO						
Mentions related to article 134, paragraphs 4 and 5 from the Companies Code						
. Auditor's fees according to a mandate at the group level led by the company publishing the information	9507	1.406	*	*	7	*
. Fees for exceptional services or special missions executed in these group by the auditor						
- Other attestation missions	95071	49	*	*	4	*
- Tax consultancy	95072		*	*		*
- Other missions external to the audit	95073	96	*	*	2	*
. Fees to people auditors are linked to according to the mandate at the group level led by the company publishing the information	9509	161	*	*	3	*
. Fees for exceptional services or special missions executed in the group by people they are linked to						
- Other attestation missions	95091		*	*		*
- Tax consultancy	95092	138	*	*	3	*
- Other missions external to the audit	95093	92	*	*	1	*

Year 2013                      Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 18

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
= = = = = 6 SOCIAL BALANCE SHEET = = = = =						
< < < Amounts in thousands of EUR > > > ("FTE" = "full-time equivalents")						
I.STATEMENT OF THE PERSONS EMPLOYED						
A.EMPLOYEES FOR WHOM THE COMPANY HAS INTRODUCED A DECLARATION DIMONA OR WHO ARE RECORDED IN THE GENERAL REGISTER OF PERSONNEL						
1.During the current and preceding period						
AVERAGE NUMBER OF EMPLOYEES						
. Full-time	1001	*	432	*	*	34
. Part-time	1002	*	115	*	*	32
. Total in FTE (current period)	1003	*	507	*	*	39
. Total in FTE (preceding period)	1003P	*	437	*	*	31
NUMBER OF HOURS ACTUALLY WORKED						
. Full-time	1011	*	664.532	*	*	34
. Part-time	1012	*	127.676	*	*	32
. Total (current period)	1013	*	792.208	*	*	39
. Total (preceding period)	1013P	*	686.656	*	*	31
PERSONNEL COSTS						
. Full-time	1021	*	20.126	*	*	34
. Part-time	1022	*	4.059	*	*	32
. Total (current period)	1023	*	24.184	*	*	39
. Total (preceding period)	1023P	*	20.406	*	*	31
1.During the current period						
a)AVERAGE NUMBER OF EMPLOYEES						
Full-time						
. Total	1001	18.607	*	*	49	*
. Men	10011	11.344	*	*	48	*
. Women	10012	7.230	*	*	45	*
Part-time						
. Total	1002	3.714	*	*	45	*
. Men	10021	767	*	*	34	*
. Women	10022	2.944	*	*	43	*
Total in FTE						
. Total	1003	21.344	*	*	49	*
. Men	10031	11.896	*	*	48	*
. Women	10032	9.414	*	*	45	*
b)NUMBER OF HOURS ACTUALLY WORKED						
Full-time						
. Total	1011	27.639.674	*	*	49	*
. Men	10111	17.278.744	*	*	48	*
. Women	10112	10.310.110	*	*	45	*
Part-time						
. Total	1012	4.315.555	*	*	45	*
. Men	10121	1.006.638	*	*	35	*
. Women	10122	3.305.906	*	*	43	*
Total						
. Total	1013	31.955.229	*	*	49	*
. Men	10131	18.285.382	*	*	48	*
. Women	10132	13.616.016	*	*	45	*
c)PERSONNEL COSTS						
Full-time						
. Total	1021	1.733.872	*	*	49	*
. Men	10211	1.112.517	*	*	47	*
. Women	10212	619.414	*	*	44	*
Part-time						
. Total	1022	295.111	*	*	45	*
. Men	10221	72.583	*	*	34	*
. Women	10222	222.237	*	*	42	*
Total						
. Total	1023	2.028.983	*	*	49	*
. Men	10231	1.185.100	*	*	47	*
. Women	10232	841.651	*	*	44	*
d)ADVANTAGES IN ADDITION TO WAGES						
. Total	1033	9.709	*	*	22	*
. Men	10331	5.863	*	*	22	*
. Women	10332	3.846	*	*	21	*
2.During the preceding period						
Average number of employees in FTE						
. Total	1003P	20.832	*	*	50	*
. Men	10031P	11.563	*	*	48	*
. Women	10032P	9.233	*	*	45	*
Number of hours actually worked						
. Total	1013P	31.330.112	*	*	50	*
. Men	10131P	17.988.122	*	*	48	*
. Women	10132P	13.451.457	*	*	45	*
Personnel costs						
. Total	1023P	1.916.610	*	*	50	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 19

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Men	10231P	1.119.938	*	*	47	*
. Women	10232P	790.104	*	*	44	*
Advantages in addition to wages						
. Total	1033P	15.101	*	*	21	*
. Men	10331P	8.303	*	*	20	*
. Women	10332P	6.496	*	*	19	*
2.On the closing date of the financial year						
3.On the closing date of the financial year						
a)NUMBER OF EMPLOYEES						
. Full-time	1051	18.874	440	19.314	49	33
. Part-time	1052	3.677	122	3.799	43	31
. Total in FTE	1053	21.609	524	22.132	49	38
b)BY NATURE OF THE EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	1101	17.158	413	17.571	49	32
. Part-time	1102	3.657	121	3.778	43	31
. Total in FTE	1103	19.879	496	20.375	49	38
Contract for a definite period						
. Full-time	1111	1.609	24	1.633	27	11
. Part-time	1112	19	1	20	10	1
. Total in FTE	1113	1.623	25	1.647	28	12
Contract for the execution of						
a specifically assigned work						
. Full-time	1121	23	2	25	3	2
. Part-time	1122					
. Total in FTE	1123	23	2	25	3	2
Replacement contract						
. Full-time	1131	84	1	85	8	1
. Part-time	1132	1		1	1	
. Total in FTE	1133	85	1	86	8	1
c)ACCORDING TO GENDER AND STUDY LEVEL						
Men						
. Full-time	1201	11.529	221	11.750	48	28
. Part-time	1202	733	21	754	30	12
. Total in FTE	1203	12.069	234	12.303	48	31
- primary education						
. Full-time	12001	386	24	410	17	5
. Part-time	12002	28	1	29	7	1
. Total in FTE	12003	407	25	432	19	5
- secondary education						
. Full-time	12011	4.730	135	4.865	38	21
. Part-time	12012	445	14	459	23	9
. Total in FTE	12013	5.060	145	5.205	38	23
- higher non-university education						
. Full-time	12021	3.558	27	3.585	44	14
. Part-time	12022	201	3	204	21	3
. Total in FTE	12023	3.707	28	3.735	44	15
- university education						
. Full-time	12031	2.855	30	2.885	44	13
. Part-time	12032	59	1	60	16	1
. Total in FTE	12033	2.895	30	2.925	45	13
Women						
. Full-time	1211	7.345	219	7.564	46	31
. Part-time	1212	2.944	101	3.045	43	28
. Total in FTE	1213	9.540	290	9.830	46	37
- primary education						
. Full-time	12101	329	23	352	16	6
. Part-time	12102	110	12	122	10	5
. Total in FTE	12103	404	32	436	17	8
- secondary education						
. Full-time	12111	2.441	128	2.569	38	21
. Part-time	12112	1.320	58	1.378	39	21
. Total in FTE	12113	3.389	168	3.557	42	26
- higher non-university education						
. Full-time	12121	2.347	30	2.377	42	15
. Part-time	12122	1.053	13	1.066	40	10
. Total in FTE	12123	3.166	39	3.205	44	19
- university education						
. Full-time	12131	2.228	28	2.256	40	14
. Part-time	12132	461	11	472	32	7
. Total in FTE	12133	2.581	36	2.616	42	17
d)BY PROFESSIONAL CATEGORY						
Management staff						
. Full-time	1301	382	2	384	26	1
. Part-time	1302	14		14	8	
. Total in FTE	1303	393	2	395	26	1
Employees						
. Full-time	1341	13.411	213	13.624	49	32
. Part-time	1342	2.321	66	2.387	42	25
. Total in FTE	1343	15.171	259	15.430	49	35
Workers						
. Full-time	1321	5.072	223	5.295	30	20

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 20

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Part-time	1322	1.341	56	1.397	24	18
. Total in FTE	1323	6.035	261	6.295	30	25
Others						
. Full-time	1331	9	2	11	4	1
. Part-time	1332	1		1	1	
. Total in FTE	1333	10	2	12	5	1
SPECIFICALLY FOR COMPLETE FORMS :						
B.HIRED TEMPORARY STAFF AND PERSONS PLACED AT THE ENTERPRISE'S DISPOSAL DURING CURRENT PERIOD						
a)HIRED TEMPORARY STAFF						
. Average number of persons employed	1501	1.163	*	*	34	*
. Number of hours actually worked	1511	2.187.353	*	*	34	*
. Costs for the enterprise	1521	67.265	*	*	34	*
b)PERSONS PLACED AT THE ENTERPRISE'S DISPOSAL						
. Average number of persons employed	1502	55	*	*	5	*
. Number of hours actually worked	1512	109.309	*	*	5	*
. Costs for the enterprise	1522	5.569	*	*	5	*
II.LIST OF PERSONNEL MOVEMENTS DURING THE ACCOUNTING PERIOD						
A.ENTRIES						
a)NUMBER OF EMPLOYEES FOR WHOM THE COMPANY HAS INTRODUCED A DECLARATION DIMONA OR WHO WERE INSCRIBED TO THE GENERAL REGISTER DURING THE ACCOUNTING PERIOD						
. Full-time	2051	2.323	258	2.581	43	27
. Part-time	2052	50	34	84	24	17
. Total in FTE	2053	2.358	279	2.636	43	33
SPECIFICALLY FOR COMPLETE FORMS :						
b)BY TYPE OF EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	2101	1.116	*	*	41	*
. Part-time	2102	40	*	*	21	*
. Total in FTE	2103	1.144	*	*	42	*
Contract for a definite period						
. Full-time	2111	1.087	*	*	28	*
. Part-time	2112	7	*	*	4	*
. Total in FTE	2113	1.092	*	*	28	*
Contract for the execution of a specifically assigned work						
. Full-time	2121	68	*	*	3	*
. Part-time	2122	1	*	*	1	*
. Total in FTE	2123	69	*	*	3	*
Replacement contract						
. Full-time	2131	52	*	*	7	*
. Part-time	2132	2	*	*	1	*
. Total in FTE	2133	53	*	*	7	*
B.DEPARTURES						
a)NUMBER OF EMPLOYEES WHOSE CONTRACT-TERMINATION DATE HAS BEEN ENTERED IN A DECLARATION DIMONA OR IN THE REGISTER GENERAL OF PERSONNEL DURING THE ACCOUNTING PERIOD						
. Full-time	3051	1.621	192	1.813	47	23
. Part-time	3052	235	29	264	32	16
. Total in FTE	3053	1.764	209	1.973	48	27
SPECIFICALLY FOR COMPLETE FORMS :						
b)BY TYPE OF EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	3101	936	*	*	46	*
. Part-time	3102	222	*	*	31	*
. Total in FTE	3103	1.070	*	*	47	*
Contract for a definite period						
. Full-time	3111	628	*	*	29	*
. Part-time	3112	10	*	*	7	*
. Total in FTE	3113	635	*	*	29	*
Contract for the execution of a specifically assigned work						
. Full-time	3121	5	*	*	1	*
. Part-time	3122		*	*		*
. Total in FTE	3123	5	*	*	1	*
Replacement contract						
. Full-time	3131	52	*	*	8	*
. Part-time	3132	3	*	*	2	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 21

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Total in FTE	3133	54	*	*	8	*
c)BY REASON OF TERMINATION OF CONTRACT						
Retirement						
. Full-time	3401	36	*	*	17	*
. Part-time	3402	14	*	*	9	*
. Total in FTE	3403	44	*	*	19	*
Unemployment with extra allowance from enterprise						
. Full-time	3411	63	*	*	12	*
. Part-time	3412	51	*	*	12	*
. Total in FTE	3413	97	*	*	15	*
Dismissal						
. Full-time	3421	284	*	*	32	*
. Part-time	3422	48	*	*	14	*
. Total in FTE	3423	316	*	*	32	*
Other reason						
. Full-time	3431	1.238	*	*	45	*
. Part-time	3432	122	*	*	27	*
. Total in FTE	3433	1.307	*	*	45	*
of which: number of persons who continue to render services to the enterprise at least half-time on a self-employed basis:						
. Full-time	3501	2	*	*	1	*
. Part-time	3502		*	*		*
. Total in FTE	3503	2	*	*	1	*
III.INFORMATION ON TRAINING PROVIDED TO EMPLOYEES DURING THE ACCOUNTING PERIOD						
a)Total of initiatives of formal professional training at the expense of the employer						
Men						
. Number of employees involved	5801	10.948	24	10.972	36	3
. Number of actual training hours	5802	320.085	208	320.293	36	3
. Costs for the enterprise	5803	19.913	12	19.924	39	5
- of which gross costs directly linked to training	58031	19.905	11	19.916	36	3
- of which fees paid and payments to collective funds	58032	135	1	136	20	2
- of which grants and other financial advantages received (to deduct)	58033	128		128	8	
Women						
. Number of employees involved	5811	8.466	19	8.485	37	4
. Number of actual training hours	5812	222.747	498	223.245	37	4
. Costs for the enterprise	5813	13.991	38	14.030	38	6
- of which gross costs directly linked to training	58131	14.069	39	14.108	37	4
- of which fees paid and payments to collective funds	58132	104	1	104	20	3
- of which grants and other financial advantages received (to deduct)	58133	181	2	183	7	2
b)Total of initiatives of less formal or informal professional training at the expense of the employer						
Men						
. Number of employees involved	5821	2.314	20	2.334	18	2
. Number of actual training hours	5822	156.858	1.008	157.866	18	2
. Costs for the enterprise	5823	6.999	9	7.008	18	2
Women						
. Number of employees involved	5831	2.241	3	2.244	17	1
. Number of actual training hours	5832	112.706	6	112.712	17	1
. Costs for the enterprise	5833	5.117	0	5.117	17	1
c)Total of initiatives of initial professional training at the expense of the employer						
Men						
. Number of employees involved	5841	414	8	422	6	3
. Number of actual training hours	5842	98.954	347	99.301	6	3
. Costs for the enterprise	5843	4.380	11	4.391	6	3
Women						
. Number of employees involved	5851	274	20	294	6	1
. Number of actual training hours	5852	65.412	297	65.709	6	1
. Costs for the enterprise	5853	2.929	18	2.947	6	1

Year 2013      Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 22

The value of the ratios below is equal to or greater than: Q1 in 75% of the enterprises Q2 in 50% of the enterprises Q3 in 25% of the enterprises		Q1	Q2	Q3	Number of enterprises	Ratios calculated from the globalised amounts
= = = = = FINANCIAL RATIOS = = = = =						
1. Gross operating margin	(%)	-8,7	8,8	13,8	52	31,3
2. Net operating margin	(%)	-16,7	4,0	7,5	52	8,5
3. Added value / operating income	(%)	13,3	30,9	46,7	52	42,2
4. Added value / person employed (EUR)		62.524	96.337	135.086	49	269.545
5. Added value / Tangible fixed assets	(%)	18,2	37,3	99,7	51	65,6
6. Personnel charges / Added value	(%)	46,7	67,9	76,7	42	36,8
7. Depreciation, depreciation allowances and provisions for risks and costs / Added value	(%)	7,4	13,7	20,9	42	45,3
8. Debt charges / Added value	(%)	0,2	0,8	3,5	40	3,7
9. Return on equity after tax	(%)	0,4	5,0	11,9	52	4,6
10. Cash-flow / Equity	(%)	2,5	16,8	31,8	52	13,7
11. Gross return on total assets before taxes and debt charges	(%)	-0,4	8,5	13,2	55	11,0
12. Net return on total assets before taxes and debt charges	(%)	-3,7	3,9	7,3	55	4,1
13. Liquidity in broad sense		0,86	1,35	2,45	54	2,19
14. Liquidity in narrow sense		0,46	0,86	2,37	54	1,75
15.1 Stock turnover of raw material and consumables (except for the building industry)		2,4	3,4	5,2	39	3,2
15.2 Stock turnover of raw material and consumables (only for the building industry)		*	*	*	*	*
16.1 Stock turnover of goods being processed and finished goods (except for the building industry)		6,6	10,5	24,0	31	5,2
16.2 Stock turnover of goods being processed and finished goods (only for the building industry)		*	*	*	*	*
17. Number of days of customer credit		27	66	92	52	82
18. Number of days of supplier credit		45	64	102	55	96
19. Equity / Total liabilities and equity	(%)	30,0	52,0	76,8	55	75,2
20. Acquisition of tangible assets / Added value	(%)	3,5	7,9	20,5	41	13,0
21. Acquisition of tangible assets / Tangible assets at the end of the preceding financial year	(%)	5,5	22,3	31,2	45	22,9

Year 2013      Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 23

The value of the ratios below is equal to or greater than: Q1 in 75% of the enterprises Q2 in 50% of the enterprises Q3 in 25% of the enterprises		Q1	Q2	Q3	Number of enterprises	Ratios calculated from the globalised amounts
= = = = = FINANCIAL RATIOS = = = = =						
1. Gross operating margin	(%)	n.s.	n.s.	n.s.	n.s.	19,9
2. Net operating margin	(%)	n.s.	n.s.	n.s.	n.s.	3,4
3. Added value / operating income	(%)	n.s.	n.s.	n.s.	n.s.	38,0
4. Added value / person employed (EUR)		38.384	69.225	91.305	34	83.254
5. Added value / Tangible fixed assets	(%)	-0,2	27,9	91,5	78	49,1
6. Personnel charges / Added value	(%)	39,3	58,2	80,9	34	57,3
7. Depreciation, depreciation allowances and provisions for risks and costs / Added value	(%)	11,2	28,6	60,8	60	31,6
8. Financial charges / Added value	(%)	0,8	4,8	13,3	61	12,5
9. Return on equity after tax	(%)	-5,9	7,0	31,8	74	14,4
10. Cash-flow / Equity	(%)	-0,4	22,3	49,9	74	24,8
11. Gross return on total assets before taxes and financial charges	(%)	-7,0	9,4	23,2	93	16,7
12. Net return on total assets before taxes and financial charges	(%)	-9,6	3,4	14,0	93	11,6
13. Liquidity in broad sense		0,72	1,44	3,16	92	1,33
14. Liquidity in narrow sense		0,50	1,17	2,92	92	1,12
17. Number of days of customer credit		n.s.	n.s.	n.s.	n.s.	78
18. Number of days of supplier credit		n.s.	n.s.	n.s.	n.s.	60
19. Equity / Total liabilities and equity	(%)	9,1	34,3	63,8	93	41,9
20. Acquisition of tangible assets / Added value	(%)	5,9	13,3	29,7	50	51,1
21. Acquisition of tangible assets / Tangible assets at the end of the preceding financial year	(%)	3,4	16,8	47,8	48	11,7

Year 2013      Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 24

The value of the ratios below is equal to or greater than: Q1 in 75% of the enterprises Q2 in 50% of the enterprises Q3 in 25% of the enterprises		Q1	Q2	Q3	Number of enterprises	Ratios calculated from the globalised amounts
= = = = = FINANCIAL RATIOS = = = = =						
1. Gross operating margin	(%)	1,2	10,5	17,5	55	37,0
2. Net operating margin	(%)	0,0	4,7	8,6	55	10,5
3. Added value / operating income	(%)	13,5	30,7	47,2	61	42,3
4. Added value / person employed (EUR)		54.360	83.576	121.531	83	266.128
5. Added value / Tangible fixed assets	(%)	8,1	32,0	97,7	129	65,6
6. Personnel charges / Added value	(%)	45,3	65,0	78,5	76	36,3
7. Depreciation, depreciation allowances and provisions for risks and costs / Added value	(%)	10,0	17,8	39,8	102	45,6
8. Financial charges / Added value	(%)	0,8	3,2	12,6	104	5,7
9. Return on equity after tax	(%)	-4,6	5,7	20,0	126	4,6
10. Cash-flow / Equity	(%)	-0,1	17,7	42,7	126	13,6
11. Gross return on total assets before taxes and financial charges	(%)	-4,3	9,3	19,7	148	11,2
12. Net return on total assets before taxes and financial charges	(%)	-7,3	3,6	11,3	148	4,4
13. Liquidity in broad sense		0,82	1,41	2,88	146	2,19
14. Liquidity in narrow sense		0,49	1,05	2,45	146	1,75
17. Number of days of customer credit		36	71	108	55	108
18. Number of days of supplier credit		49	75	124	64	120
19. Equity / Total liabilities and equity	(%)	16,9	39,4	72,0	148	75,1
20. Acquisition of tangible assets / Added value	(%)	3,7	12,7	21,3	91	13,2
21. Acquisition of tangible assets / Tangible assets at the end of the preceding financial year	(%)	4,5	19,2	33,4	93	22,7





Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 1

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
= = = = = 6 SOCIAL BALANCE SHEET = = = = =						
< < < Amounts in thousands of EUR > > > > ("FTE" = "full-time equivalents")						
I.STATEMENT OF THE PERSONS EMPLOYED						
A.EMPLOYEES FOR WHOM THE COMPANY HAS INTRODUCED A DECLARATION DIMONA OR WHO ARE RECORDED IN THE GENERAL REGISTER OF PERSONNEL						
1.During the current and preceding period						
AVERAGE NUMBER OF EMPLOYEES						
. Full-time	1001	*	432	*	*	34
. Part-time	1002	*	115	*	*	32
. Total in FTE (current period)	1003	*	507	*	*	39
. Total in FTE (preceding period)	1003P	*	437	*	*	31
NUMBER OF HOURS ACTUALLY WORKED						
. Full-time	1011	*	664.532	*	*	34
. Part-time	1012	*	127.676	*	*	32
. Total (current period)	1013	*	792.208	*	*	39
. Total (preceding period)	1013P	*	686.656	*	*	31
PERSONNEL COSTS						
. Full-time	1021	*	20.126	*	*	34
. Part-time	1022	*	4.059	*	*	32
. Total (current period)	1023	*	24.184	*	*	39
. Total (preceding period)	1023P	*	20.406	*	*	31
1.During the current period						
a)AVERAGE NUMBER OF EMPLOYEES						
Full-time						
. Total	1001	18.607	*	*	49	*
. Men	10011	11.344	*	*	48	*
. Women	10012	7.230	*	*	45	*
Part-time						
. Total	1002	3.714	*	*	45	*
. Men	10021	767	*	*	34	*
. Women	10022	2.944	*	*	43	*
Total in FTE						
. Total	1003	21.344	*	*	49	*
. Men	10031	11.896	*	*	48	*
. Women	10032	9.414	*	*	45	*
b)NUMBER OF HOURS ACTUALLY WORKED						
Full-time						
. Total	1011	27.639.674	*	*	49	*
. Men	10111	17.278.744	*	*	48	*
. Women	10112	10.310.110	*	*	45	*
Part-time						
. Total	1012	4.315.555	*	*	45	*
. Men	10121	1.006.638	*	*	35	*
. Women	10122	3.305.906	*	*	43	*
Total						
. Total	1013	31.955.229	*	*	49	*
. Men	10131	18.285.382	*	*	48	*
. Women	10132	13.616.016	*	*	45	*
c)PERSONNEL COSTS						
Full-time						
. Total	1021	1.733.872	*	*	49	*
. Men	10211	1.112.517	*	*	47	*
. Women	10212	619.414	*	*	44	*
Part-time						
. Total	1022	295.111	*	*	45	*
. Men	10221	72.583	*	*	34	*
. Women	10222	222.237	*	*	42	*
Total						
. Total	1023	2.028.983	*	*	49	*
. Men	10231	1.185.100	*	*	47	*
. Women	10232	841.651	*	*	44	*
d)ADVANTAGES IN ADDITION TO WAGES						
. Total	1033	9.709	*	*	22	*
. Men	10331	5.863	*	*	22	*
. Women	10332	3.846	*	*	21	*
2.During the preceding period						
Average number of employees in FTE						
. Total	1003P	20.832	*	*	50	*
. Men	10031P	11.563	*	*	48	*
. Women	10032P	9.233	*	*	45	*
Number of hours actually worked						
. Total	1013P	31.330.112	*	*	50	*
. Men	10131P	17.988.122	*	*	48	*
. Women	10132P	13.451.457	*	*	45	*
Personnel costs						
. Total	1023P	1.916.610	*	*	50	*
. Men	10231P	1.119.938	*	*	47	*

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 2

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Women	10232P	790.104	*	*	44	*
Advantages in addition to wages						
. Total	1033P	15.101	*	*	21	*
. Men	10331P	8.303	*	*	20	*
. Women	10332P	6.496	*	*	19	*
2.On the closing date of the financial year						
3.On the closing date of the financial year						
a)NUMBER OF EMPLOYEES						
. Full-time	1051	18.874	440	19.314	49	33
. Part-time	1052	3.677	122	3.799	43	31
. Total in FTE	1053	21.609	524	22.132	49	38
b)BY NATURE OF THE EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	1101	17.158	413	17.571	49	32
. Part-time	1102	3.657	121	3.778	43	31
. Total in FTE	1103	19.879	496	20.375	49	38
Contract for a definite period						
. Full-time	1111	1.609	24	1.633	27	11
. Part-time	1112	19	1	20	10	1
. Total in FTE	1113	1.623	25	1.647	28	12
Contract for the execution of a specifically assigned work						
. Full-time	1121	23	2	25	3	2
. Part-time	1122					
. Total in FTE	1123	23	2	25	3	2
Replacement contract						
. Full-time	1131	84	1	85	8	1
. Part-time	1132	1		1	1	
. Total in FTE	1133	85	1	86	8	1
c)ACCORDING TO GENDER AND STUDY LEVEL						
Men						
. Full-time	1201	11.529	221	11.750	48	28
. Part-time	1202	733	21	754	30	12
. Total in FTE	1203	12.069	234	12.303	48	31
- primary education						
. Full-time	12001	386	24	410	17	5
. Part-time	12002	28	1	29	7	1
. Total in FTE	12003	407	25	432	19	5
- secondary education						
. Full-time	12011	4.730	135	4.865	38	21
. Part-time	12012	445	14	459	23	9
. Total in FTE	12013	5.060	145	5.205	38	23
- higher non-university education						
. Full-time	12021	3.558	27	3.585	44	14
. Part-time	12022	201	3	204	21	3
. Total in FTE	12023	3.707	28	3.735	44	15
- university education						
. Full-time	12031	2.855	30	2.885	44	13
. Part-time	12032	59	1	60	16	1
. Total in FTE	12033	2.895	30	2.925	45	13
Women						
. Full-time	1211	7.345	219	7.564	46	31
. Part-time	1212	2.944	101	3.045	43	28
. Total in FTE	1213	9.540	290	9.830	46	37
- primary education						
. Full-time	12101	329	23	352	16	6
. Part-time	12102	110	12	122	10	5
. Total in FTE	12103	404	32	436	17	8
- secondary education						
. Full-time	12111	2.441	128	2.569	38	21
. Part-time	12112	1.320	58	1.378	39	21
. Total in FTE	12113	3.389	168	3.557	42	26
- higher non-university education						
. Full-time	12121	2.347	30	2.377	42	15
. Part-time	12122	1.053	13	1.066	40	10
. Total in FTE	12123	3.166	39	3.205	44	19
- university education						
. Full-time	12131	2.228	28	2.256	40	14
. Part-time	12132	461	11	472	32	7
. Total in FTE	12133	2.581	36	2.616	42	17
d)BY PROFESSIONAL CATEGORY						
Management staff						
. Full-time	1301	382	2	384	26	1
. Part-time	1302	14		14	8	
. Total in FTE	1303	393	2	395	26	1
Employees						
. Full-time	1341	13.411	213	13.624	49	32
. Part-time	1342	2.321	66	2.387	42	25
. Total in FTE	1343	15.171	259	15.430	49	35
Workers						
. Full-time	1321	5.072	223	5.295	30	20
. Part-time	1322	1.341	56	1.397	24	18

NACE-BEL2008: + 21\*

P. 3

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
. Total in FTE	1323	6.035	261	6.295	30	25
Others						
. Full-time	1331	9	2	11	4	1
. Part-time	1332	1		1	1	
. Total in FTE	1333	10	2	12	5	1
SPECIFICALLY FOR COMPLETE FORMS :						
B.HIRED TEMPORARY STAFF AND PERSONS PLACED AT THE ENTERPRISE'S DISPOSAL DURING CURRENT PERIOD						
a)HIRED TEMPORARY STAFF						
. Average number of persons employed	1501	1.163	*	*	34	*
. Number of hours actually worked	1511	2.187.353	*	*	34	*
. Costs for the enterprise	1521	67.265	*	*	34	*
b)PERSONS PLACED AT THE ENTERPRISE'S DISPOSAL						
. Average number of persons employed	1502	55	*	*	5	*
. Number of hours actually worked	1512	109.309	*	*	5	*
. Costs for the enterprise	1522	5.569	*	*	5	*
II.LIST OF PERSONNEL MOVEMENTS DURING THE ACCOUNTING PERIOD						
A.ENTRIES						
a)NUMBER OF EMPLOYEES FOR WHOM THE COMPANY HAS INTRODUCED A DECLARATION DIMONA OR WHO WERE INSCRIBED TO THE GENERAL REGISTER DURING THE ACCOUNTING PERIOD						
. Full-time	2051	2.323	258	2.581	43	27
. Part-time	2052	50	34	84	24	17
. Total in FTE	2053	2.358	279	2.636	43	33
SPECIFICALLY FOR COMPLETE FORMS :						
b)BY TYPE OF EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	2101	1.116	*	*	41	*
. Part-time	2102	40	*	*	21	*
. Total in FTE	2103	1.144	*	*	42	*
Contract for a definite period						
. Full-time	2111	1.087	*	*	28	*
. Part-time	2112	7	*	*	4	*
. Total in FTE	2113	1.092	*	*	28	*
Contract for the execution of a specifically assigned work						
. Full-time	2121	68	*	*	3	*
. Part-time	2122	1	*	*	1	*
. Total in FTE	2123	69	*	*	3	*
Replacement contract						
. Full-time	2131	52	*	*	7	*
. Part-time	2132	2	*	*	1	*
. Total in FTE	2133	53	*	*	7	*
B.DEPARTURES						
a)NUMBER OF EMPLOYEES WHOSE CONTRACT-TERMINATION DATE HAS BEEN ENTERED IN A DECLARATION DIMONA OR IN THE REGISTER GENERAL OF PERSONNEL DURING THE ACCOUNTING PERIOD						
. Full-time	3051	1.621	192	1.813	47	23
. Part-time	3052	235	29	264	32	16
. Total in FTE	3053	1.764	209	1.973	48	27
SPECIFICALLY FOR COMPLETE FORMS :						
b)BY TYPE OF EMPLOYMENT CONTRACT						
Contract for an indefinite period						
. Full-time	3101	936	*	*	46	*
. Part-time	3102	222	*	*	31	*
. Total in FTE	3103	1.070	*	*	47	*
Contract for a definite period						
. Full-time	3111	628	*	*	29	*
. Part-time	3112	10	*	*	7	*
. Total in FTE	3113	635	*	*	29	*
Contract for the execution of a specifically assigned work						
. Full-time	3121	5	*	*	1	*
. Part-time	3122		*	*		*
. Total in FTE	3123	5	*	*	1	*
Replacement contract						
. Full-time	3131	52	*	*	8	*
. Part-time	3132	3	*	*	2	*
. Total in FTE	3133	54	*	*	8	*
c)BY REASON OF TERMINATION						

Year 2013 Grouping : DE244 - Manufacture of pharmaceutical products

NACE-BEL2008: + 21\*

P. 4

	Codes	AMOUNTS			NUM. OF ENTERP.	
		Complete	Abbreviated	Total	Comp.	Abbr.
OF CONTRACT						
Retirement						
. Full-time	3401	36	*	*	17	*
. Part-time	3402	14	*	*	9	*
. Total in FTE	3403	44	*	*	19	*
Unemployment with extra allowance from enterprise						
. Full-time	3411	63	*	*	12	*
. Part-time	3412	51	*	*	12	*
. Total in FTE	3413	97	*	*	15	*
Dismissal						
. Full-time	3421	284	*	*	32	*
. Part-time	3422	48	*	*	14	*
. Total in FTE	3423	316	*	*	32	*
Other reason						
. Full-time	3431	1.238	*	*	45	*
. Part-time	3432	122	*	*	27	*
. Total in FTE	3433	1.307	*	*	45	*
of which: number of persons who continue to render services to the enterprise at least half-time on a self-employed basis:						
. Full-time	3501	2	*	*	1	*
. Part-time	3502		*	*		*
. Total in FTE	3503	2	*	*	1	*
III.INFORMATION ON TRAINING PROVIDED TO EMPLOYEES DURING THE ACCOUNTING PERIOD						
a)Total of initiatives of formal professional training at the expense of the employer						
Men						
. Number of employees involved	5801	10.948	24	10.972	36	3
. Number of actual training hours	5802	320.085	208	320.293	36	3
. Costs for the enterprise	5803	19.913	12	19.924	39	5
- of which gross costs directly linked to training	58031	19.905	11	19.916	36	3
- of which fees paid and payments to collective funds	58032	135	1	136	20	2
- of which grants and other financial advantages received (to deduct)	58033	128		128	8	
Women						
. Number of employees involved	5811	8.466	19	8.485	37	4
. Number of actual training hours	5812	222.747	498	223.245	37	4
. Costs for the enterprise	5813	13.991	38	14.030	38	6
- of which gross costs directly linked to training	58131	14.069	39	14.108	37	4
- of which fees paid and payments to collective funds	58132	104	1	104	20	3
- of which grants and other financial advantages received (to deduct)	58133	181	2	183	7	2
b)Total of initiatives of less formal or informal professional training at the expense of the employer						
Men						
. Number of employees involved	5821	2.314	20	2.334	18	2
. Number of actual training hours	5822	156.858	1.008	157.866	18	2
. Costs for the enterprise	5823	6.999	9	7.008	18	2
Women						
. Number of employees involved	5831	2.241	3	2.244	17	1
. Number of actual training hours	5832	112.706	6	112.712	17	1
. Costs for the enterprise	5833	5.117	0	5.117	17	1
c)Total of initiatives of initial professional training at the expense of the employer						
Men						
. Number of employees involved	5841	414	8	422	6	3
. Number of actual training hours	5842	98.954	347	99.301	6	3
. Costs for the enterprise	5843	4.380	11	4.391	6	3
Women						
. Number of employees involved	5851	274	20	294	6	1
. Number of actual training hours	5852	65.412	297	65.709	6	1
. Costs for the enterprise	5853	2.929	18	2.947	6	1